Press release
Unlocking the Potential of Dry Age-Related Macular Degeneration Therapies: DelveInsight's Comprehensive Report Sheds Light on the Future of Dry Age-Related Macular Degeneration Treatment | Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Te
Dry Age-Related Macular Degeneration Pipeline
In the Dry Age-Related Macular Degeneration pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Dry Age-Related Macular Degeneration NDA approvals (if any), and product development activities comprising the technology, Dry Age-related Macular Degeneration collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Dry Age-Related Macular Degeneration pipeline treatment landscape of the report, click here @ Dry Age-Related Macular Degeneration Pipeline- https://www.delveinsight.com/report-store/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Dry Age-Related Macular Degeneration Pipeline Report
• DelveInsight's Dry Age-Related Macular Degeneration Pipeline analysis depicts a robust space with 58+ active players working to develop 64+ pipeline treatment therapies.
• The leading Dry Age-Related Macular Degeneration Companies working in the market include Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Technologies, Aevitas Therapeutics, NGM Biopharmaceuticals, InflammX Therapeutics, Lineage Cell Therapeutics, Alexion AstraZeneca Rare Disease, Belite Bio, Katairo, Cognition Therapeutics, Apellis Pharmaceuticals, Galimedix Therapeutics, Amarna Therapeutics, 4D Molecular Therapeutics, Aviceda Therapeutics, Isarna Therapeutics, and others.
• Promising Dry Age-related Macular Degeneration Pipeline Therapies in the various stages of development include GT005: Medium Dose, unoprostone isopropyl, ACU-4429, QA102, Fenretinide, Risuteganib, Tinlarebant (LBS-008), Zimura, ARC1905, ASP7317, and others.
• On January 2023, Luxa Biotechnology Inc announced a study of phase 1 & 2 for RPESC-RPE-4W. The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W as therapy for dry AMD.
• On February 2023, RBP4 Pty Ltd announced a study of phase 1 clinical trials for Tinlarebant (LBS-008). This is a Phase 1b, parallel single-dose study to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of Tinlarebant when administered as an oral dose to elderly healthy volunteers. This study will evaluate 2 dose levels in 2 cohorts comprising up to a total of 16 participants (8 per cohort). Dose levels will be evaluated in parallel.
• On April 2023, Smilebiotek Zhuhai Limited announced a study of phase 2 clinical trials for QA102. This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of GA or CNV in high-risk eyes.
Dry Age-Related Macular Degeneration Overview
Age-related macular degeneration (AMD) is a degenerative disease of the center area of the ocular-posterior segment (the macula lutea) that causes slow degeneration in central vision and severe disability in affected persons. "Age-related" means that it mainly occurs with elderly adults, while "Macular" means that the macula part of the eye is damaged.
To explore more information on the latest breakthroughs in the Dry Age-Related Macular Degeneration Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Dry Age-Related Macular Degeneration Emerging Drugs Profile
• ALK-001: Alkeus Pharmaceuticals
• Elamipretide: Stealth BioTherapeutics
• CPCB-RPE1: Regenerative Patch Technologies
• AAV.sFH: Aevitas Therapeutics
Dry Age-Related Macular Degeneration Pipeline Therapeutics Assessment
There are approx. 55+ key companies which are developing the therapies for Dry Age-related Macular Degeneration. The Dry Age-Related Macular Degeneration companies which have their Dry Age-related Macular Degeneration drug candidates in the most advanced stage, i.e. Phase III include, Alkeus Pharmaceuticals.
Request a sample and discover the recent advances in Dry Age-Related Macular Degeneration Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Dry Age-Related Macular Degeneration Drugs and Companies
• Active Comparator CT1812: Cognition Therapeutics
• Zimura: IVERIC Bio Inc
• ARC1905: Ophthotech Corporation
• Emixustat HCl Tablet: Kubota Vision Inc
• MC-1101: MacuClear Inc
• ASP7317: Astellas Pharma Inc
Dry Age-Related Macular Degeneration Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Dry Age-Related Macular Degeneration Therapeutics Market include-
Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Technologies, Aevitas Therapeutics, NGM Biopharmaceuticals, InflammX Therapeutics, Lineage Cell Therapeutics, Alexion AstraZeneca Rare Disease, Belite Bio, Katairo, Cognition Therapeutics, Apellis Pharmaceuticals, Galimedix Therapeutics, Amarna Therapeutics, 4D Molecular Therapeutics, Aviceda Therapeutics, Isarna Therapeutics, and others.
Dive deep into rich insights for drugs for Dry Age-Related Macular Degeneration Pipeline, click here for Dry Age-Related Macular Degeneration Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Dry Age-Related Macular Degeneration Pipeline Report
• Coverage- Global
• Dry Age-Related Macular Degeneration Companies- Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Technologies, Aevitas Therapeutics, NGM Biopharmaceuticals, InflammX Therapeutics, Lineage Cell Therapeutics, Alexion AstraZeneca Rare Disease, Belite Bio, Katairo, Cognition Therapeutics, Apellis Pharmaceuticals, Galimedix Therapeutics, Amarna Therapeutics, 4D Molecular Therapeutics, Aviceda Therapeutics, Isarna Therapeutics, and others.
• Dry Age-Related Macular Degeneration Pipeline Therapies- GT005: Medium Dose, unoprostone isopropyl, ACU-4429, QA102, Fenretinide, Risuteganib, Tinlarebant (LBS-008), Zimura, ARC1905, ASP7317, and others.
• Dry Age-Related Macular Degeneration Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Dry Age-Related Macular Degeneration Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/dry-age-macular-degeneration-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Dry Age-related Macular Degeneration: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Dry Age-related Macular Degeneration- DelveInsight's Analytical Perspective
7. Late Stage Products (Preregistration)
8. Abicipar pegol: Molecular Partners
9. Late Stage Products (Phase III)
10. ALK-001: Alkeus Pharmaceuticals
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Elamipretide: Stealth BioTherapeutics
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Drug Name: Company Name
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. AAV.sFH: Aevitas Therapeutics
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Dry Age-related Macular Degeneration Key Companies
23. Dry Age-related Macular Degeneration Key Products
24. Dry Age-related Macular Degeneration- Unmet Needs
25. Dry Age-related Macular Degeneration- Market Drivers and Barriers
26. Dry Age-related Macular Degeneration- Future Perspectives and Conclusion
27. Dry Age-related Macular Degeneration Analyst Views
28. Dry Age-related Macular Degeneration Key Companies
29. Appendix
List of Top Selling Market Research Reports in 2023
https://www.delveinsight.com/report-store/alcoholic-hepatitis-market
https://www.delveinsight.com/report-store/b-cell-maturation-antigen-targeted-therapies-market
https://www.delveinsight.com/report-store/blastomycosis-market
https://www.delveinsight.com/report-store/chronic-pulmonary-infections-due-to-pseudomonas-aeruginosa-in-patients-with-cystic-fibrosis-market
https://www.delveinsight.com/report-store/c-x-c-chemokine-receptor-inhibitors-competitive-landscape-market-and-pipeline-analysis
https://www.delveinsight.com/report-store/digestive-system-fistula-market
https://www.delveinsight.com/report-store/fertility-monitoring-devices-fertility-testing-devices-market
https://www.delveinsight.com/report-store/hay-fever-conjunctivitis-market
https://www.delveinsight.com/report-store/kawasaki-disease-market
https://www.delveinsight.com/report-store/myopia-progression-market
https://www.delveinsight.com/report-store/pecoma-market
https://www.delveinsight.com/report-store/pediatric-growth-hormone-deficiency-market
https://www.delveinsight.com/report-store/percutaneous-arterial-closure-device-market
https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
https://www.delveinsight.com/report-store/upper-tract-urothelial-cancer-market
https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
https://www.delveinsight.com/report-store/uk-healthcare-outlook-report
https://www.delveinsight.com/report-store/supraventricular-tachycardia-market
https://www.delveinsight.com/report-store/stem-cell-market
https://www.delveinsight.com/report-store/soft-tissue-defect-market
https://www.delveinsight.com/report-store/small-lymphocytic-lymphoma-market
https://www.delveinsight.com/report-store/shigella-infections-market
https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
https://www.delveinsight.com/report-store/radiation-retinopathy-market
https://www.delveinsight.com/report-store/primary-biliary-cholongitis-pbc-market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Unlocking the Potential of Dry Age-Related Macular Degeneration Therapies: DelveInsight's Comprehensive Report Sheds Light on the Future of Dry Age-Related Macular Degeneration Treatment | Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Te here
News-ID: 3142729 • Views: …
More Releases from DelveInsight Business Research
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.…
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly…
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts.
DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides…
More Releases for Macular
2025-2034 Macular Edema and Macular Degeneration Market Roadmap: Insights for Co …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
How Large Will the Macular Edema and Macular Degeneration Market Size By 2025?
In the past few years, the market size for macular edema and macular degeneration has seen significant growth. It is projected to increase from $9.65 billion in 2024 to $10.43 billion in 2025, exhibiting a compound…
Macular Edema and Macular Degeneration Market Poised for 7.1% Growth, Set to Hit …
How Are the key drivers contributing to the expansion of the macular edema and macular degeneration market?
The growth of the macular edema and macular degeneration market is predicted to be driven by the escalating number of individuals suffering from diabetes. Diabetes is a long-term health condition that results in elevated levels of glucose in the bloodstream. The condition harms the eye's blood vessels, potentially leading to macular edema and macular…
Macular Edema and Macular Degeneration Market Outlook 2025-2034: Key Trends, Gro …
"How Big Is the Macular Edema and Macular Degeneration Market Expected to Be, and What Will Its Growth Rate Be?
The macular edema and macular degeneration market has seen significant growth in recent years. It will expand from $9.65 billion in 2024 to $10.43 billion in 2025, with a CAGR of 8.1%. Factors contributing to this growth include the aging population, increasing diabetes prevalence, early diagnosis and awareness, global initiatives in…
Macular Edema and Macular Degeneration Market to Reach $22.51 Billion by 2034
The global macular edema and macular degeneration market, valued at $10.33 billion in 2023, is on track to grow at a remarkable compound annual growth rate (CAGR) of 7.34%, reaching $22.51 billion by 2034. This substantial market expansion is being fueled by rising treatment innovations, an increasing global prevalence of related diseases, and a surge in technological advancements in diagnostics and therapies.
Download White Paper: https://www.towardshealthcare.com/download-statistics/5375
Market Overview and Key Drivers
The macular…
Macular Edema and Macular Degeneration Market Size, Trends, Growth, Outlook 2024 …
"The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Macular Edema and Macular Degeneration Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $12.84…
Macular Edema and Macular Degeneration Market: Key Trends, Competitor Analysis, …
"Exploring the Global Macular Edema and Macular Degeneration Market: A Comprehensive Overview
Insights into Macular Edema and Macular Degeneration Market: Global Trends and Analysis
Macular Edema and Macular Degeneration Industry - Key Market Dynamics and Trends
The macular edema and macular degeneration market size has grown strongly in recent years. It will grow from $8.84 billion in 2023 to $9.65 billion in 2024 at a compound annual growth rate (CAGR) of 9.1%. The…
